Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Revenue of Pacira BioSciences, Inc. (PCRX)
Revenue in 2023 (TTM): $674.98 M
According to Pacira BioSciences, Inc.'s latest financial reports the company's current revenue (TTM) is $674.98 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pacira BioSciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $674.98 M | $433.02 M | $162.9 M | $61.7 M | $41.96 M |
| 2022 | $666.82 M | $467.53 M | $121.47 M | $13.3 M | $15.91 M |
| 2021 | $541.53 M | $401.28 M | $144.62 M | $56.4 M | $41.98 M |
| 2020 | $420.83 M | $303.5 M | $66.86 M | $20.09 M | $145.52 M |
| 2019 | $421.03 M | $314.31 M | $43.81 M | $-10,748,000 | $-11,016,000 |
| 2018 | $337.28 M | $250.43 M | $23.09 M | $-425,000 | $-471,000 |
| 2017 | $286.63 M | $198.72 M | $-15,824,000 | $-42,471,000 | $-42,611,000 |
| 2016 | $276.37 M | $166.27 M | $-30,783,000 | $-37,844,000 | $-37,949,000 |
| 2015 | $249 M | $177.16 M | $9.97 M | $2.12 M | $1.86 M |
| 2014 | $197.67 M | $120.23 M | $-4,942,000 | $-13,543,000 | $-13,716,000 |
| 2013 | $85.55 M | $30.78 M | $-47,330,000 | $-64,351,000 | $-63,909,000 |
| 2012 | $39.08 M | $6.95 M | $-49,134,000 | $-52,281,000 | $-52,281,000 |
| 2011 | $15.69 M | $-1,050,000 | $-29,047,000 | $-43,328,000 | $-43,328,000 |
| 2010 | $14.56 M | $2.29 M | $-18,086,000 | $-27,149,000 | $-27,149,000 |
| 2009 | $15.01 M | $2.71 M | $-24,483,000 | $-28,181,000 | $-31,707,000 |
| 2008 | $13.93 M | $-3,538,000 | $-41,308,000 | $-45,587,000 | $-41,862,000 |